Self-amplifying RNA is a revolutionary RNA platform that can amplify itself within host cells, leading to robust protein expression from a relatively small amount of RNA. This characteristic makes saRNA an attractive option for a variety of therapeutic applications, as it can potentially reduce required dosages, lower production costs, and improve patient outcomes. Recent clinical trial data has shown promising results for the technology in the treatment for advanced malignant solid tumors and rabies. Additionally, in November 2023, the world’s first formally approved saRNA-based COVID-19 vaccine was approved by Japan’s Ministry of Health, Labour and Welfare (MHLW) for initial and booster vaccinations in adults aged 18 and older.
“The introduction of self-amplifying RNA synthesis services marks a significant milestone in GenScript’s journey to accelerate the work of researchers and developers in the fast-evolving field of RNA-based therapies,” said Dr. Cedric Wu, VP of the Innovation Center at GenScript USA. “We are dedicated to providing a streamlined end-to-end service, from gene synthesis to LNP delivery, that addresses the critical needs of our customers. The addition of saRNA is a testament to our commitment to innovation and excellence.”
GenScript’s saRNA service is the culmination of extensive research and development efforts, involving the meticulous optimization of production processes, vectors, and specialized modifications, supporting early-stage research to pre-clinical development. Data from early adopters has shown that saRNA synthesized by GenScript exhibits exceptional purity and enhanced protein expression levels and duration at a much lower input than linear mRNA, ensuring reliable performance downstream.
Researchers and developers can now leverage GenScript’s expertise and robust infrastructure to access custom saRNA synthesis services, with support from GenScript’s experienced, Seattle-based technical team at every step of the way.
“We understand that the journey from research to therapy is complex and challenging,” said Ray Chen, Ph.D., President of the Life Science Group at GenScript, “With our comprehensive IVT RNA synthesis portfolio, which now includes self-amplifying RNA, along with our linear mRNA, circular RNA and lipid nanoparticle formulation services, we offer unparalleled support to our partners in their quest to develop next-generation RNA-based therapies.”
Where to learn more:
About GenScriptGenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and an integrated global cell therapy company. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 6,900 employees. As of December 31, 2023, 87,700 peer-reviewed journal articles worldwide had cited GenScript ‘s services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world.
For more information, please visit GenScript Biotech’s official website
https://www.genscript.com
Kay Chuang
Head of Marketing, GenScript
[email protected]
SOURCE GenScript Biotech Corporation
